Showing 1991-2000 of 7669 results for "".
- InnoCare Completes Patient Enrollment in Phase 2 Trial of ICP-488 for the Treatment of Psoriasishttps://practicaldermatology.com/news/innocare-completes-patient-enrollment-phase-2-trial-icp-488-treatment-psoriasis/2463108/InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis. The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the efficacy, s…
- Pilot Study Supports Once-Daily Isotretinoin for Acne Treatmenthttps://practicaldermatology.com/news/pilot-study-supports-once-daily-isotretinoin-acne-treatment/2463088/Micronized isotretinoin administered once per day without food was effective and well-tolerated for the treatment of severe nodular acne, new study results indicate. Researchers for the pilot study focused on and evaluated a regimen of once-daily micronized isotretinoin (0.4 to 0.8 mg/kg/day) witho…
- Dr. Jeanine Downie Discusses Fake Botox in TV Segmenthttps://practicaldermatology.com/news/dr-jeanine-downie-discusses-fake-botox-tv-segment/2463070/If public awareness is the key to combatting the counterfeit Botox problem that has been popping up around the country recently, then Jeanine B. Downie, MD, FAAD, took a big step May 13. Dr. Downie, an Editorial Board member for Practical Dermatology's sister publication Modern Aesthetics, joined a…
- Study: Apremilast Efficacy Shows Efficacy in Psoriasishttps://practicaldermatology.com/news/study-apremilast-efficacy-shows-efficacy-psoriasis/2463053/Results from a recent analysis suggest promise for apremilast, which showed efficacy in the treatment of patients with moderate-to-severe psoriasis. Authors publishing in Acta Dermato-Venereologica focused on the impact on skin lesions, pruritus, and serum cytokine levels. The researchers accompli…
- Consensus Statement Raises Awareness of CTCLhttps://practicaldermatology.com/news/consensus-statement-raises-awareness-ctcl/2463052/Kyowa Kirin, Inc. announced the publication of a patient-focused global consensus statement developed in collaboration with patient advocacy groups, calling on all healthcare authorities, hospitals, and clinicians to undertake 12 specific actions to enhance awareness, diagnosis, care, and support f…
- Oral HSP90 Inhibitor Gets Positive Feedback From FDAhttps://practicaldermatology.com/news/oral-hsp90-inhibitor-gets-positive-feedback-fda/2463023/A first-in-class oral drug candidate for the treatment of hidradenitis suppurativa (HS) received positive feedback from a pre-Investigational New Drug meeting with the US Food and Drug Administration (FDA), according to a press release. MC2 Therapeutics, a commercial stage biotech company focused o…
- Novel Species and Drug Resistance Found in Skin Infectionshttps://practicaldermatology.com/news/novel-species-and-drug-resistance-found-skin-infections/2463021/A recent study highlighted growing concerns within the dermatological community regarding an increase in treatment-resistant fungal strains. Researchers from The University of Texas Health Science Center at San Antonio focused their investigation on dermatophytes, a group of fungi responsible for d…
- Survey Highlights Increased Risk of Sunburn and Skin Cancer Among Outdoor Workershttps://practicaldermatology.com/news/survey-highlights-increased-risk-sunburn-and-skin-cancer-among-outdoor-workers/2463018/A recent survey conducted by the American Academy of Dermatology (AAD) highlighted the heightened risk of sunburn and skin cancer faced by outdoor workers in the United States. The survey, according to a press release, included responses from more than 1,000 U.S. adults and emphasized the construct…
- LEO Pharma Announces Topline Results of Phase 3 Trial in China for Plaque Psoriasis Treatment Enstilarhttps://practicaldermatology.com/news/leo-pharma-announces-topline-results-phase-3-trial-china-plaque-psoriasis-treatment-enstilar/2463007/LEO Pharma announced results from the Enstilar phase 3 trial in China in adult patients living with stable plaque psoriasis. The trial is a phase 3, randomised, investigator-blind, active controlled, parallel group, multicenter trial comparing the efficacy and safety of once daily Enstilar (LEO 901…
- Fish Residues Could Supply Collagenhttps://practicaldermatology.com/news/fish-residues-could-supply-collagen/2462980/Researchers in Norway believe fish residues can supplement current sources of raw materials for collagen and gelatin, according to a Phys.org article. A project called SUPREME, headed by the Norwegian science institute SINTEF Ocean in collaboration with Norwegian university NTNU and the Technical U…